CN1713890A - 控释储库制剂 - Google Patents

控释储库制剂 Download PDF

Info

Publication number
CN1713890A
CN1713890A CNA2003801039719A CN200380103971A CN1713890A CN 1713890 A CN1713890 A CN 1713890A CN A2003801039719 A CNA2003801039719 A CN A2003801039719A CN 200380103971 A CN200380103971 A CN 200380103971A CN 1713890 A CN1713890 A CN 1713890A
Authority
CN
China
Prior art keywords
composition
polymer
beneficial agent
months
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2003801039719A
Other languages
English (en)
Chinese (zh)
Inventor
陈国华
P·休斯敦
R·班尼斯特
T·卡门达
D·普里贝
L·克莱纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32312806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1713890(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of CN1713890A publication Critical patent/CN1713890A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2003801039719A 2002-11-06 2003-11-04 控释储库制剂 Pending CN1713890A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42442802P 2002-11-06 2002-11-06
US60/424,428 2002-11-06

Publications (1)

Publication Number Publication Date
CN1713890A true CN1713890A (zh) 2005-12-28

Family

ID=32312806

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2003801039719A Pending CN1713890A (zh) 2002-11-06 2003-11-04 控释储库制剂

Country Status (25)

Country Link
US (1) US7368126B2 (enExample)
EP (1) EP1581181B1 (enExample)
JP (1) JP2006508127A (enExample)
KR (1) KR20050088288A (enExample)
CN (1) CN1713890A (enExample)
AR (1) AR041913A1 (enExample)
AT (1) ATE418323T1 (enExample)
AU (1) AU2003295409B2 (enExample)
BR (1) BR0315304A (enExample)
CA (1) CA2504608C (enExample)
CL (1) CL2003002277A1 (enExample)
DE (1) DE60325511D1 (enExample)
EC (2) ECSP055838A (enExample)
MA (1) MA27523A1 (enExample)
MX (1) MXPA05004927A (enExample)
MY (1) MY140155A (enExample)
NO (1) NO20052635L (enExample)
NZ (1) NZ539810A (enExample)
PE (1) PE20040675A1 (enExample)
PL (1) PL377333A1 (enExample)
RU (1) RU2355385C2 (enExample)
TW (1) TW200503774A (enExample)
UY (1) UY28067A1 (enExample)
WO (1) WO2004043432A2 (enExample)
ZA (1) ZA200504529B (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102133180A (zh) * 2011-03-18 2011-07-27 黄芳 一种甾体5α-还原酶抑制剂长效注射制剂及其制备方法
CN105031607A (zh) * 2008-12-15 2015-11-11 诺华股份有限公司 有恒定高暴露水平的奥曲肽贮库制剂
CN105358129A (zh) * 2013-03-15 2016-02-24 赫伦治疗有限公司 聚原酸酯和质子惰性溶剂的组合物
CN105848628A (zh) * 2013-12-31 2016-08-10 Pb&B公司 用于身体重构和身体成形的受控释放脂肪酸组合物
CN111548482A (zh) * 2020-04-02 2020-08-18 复旦大学 一氧化氮供体修饰的共聚物、包含其的缓释制剂及其制备方法与应用
CN116270491A (zh) * 2023-03-30 2023-06-23 北京博恩特药业有限公司 一种醋酸亮丙瑞林缓释微球及其制备方法

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
DK1229940T3 (da) * 1999-11-15 2014-08-18 Piramal Healthcare Canada Ltd Temperaturstyret og ph-afhængig selvgelerende, vandig biopolymeropløsning
US20030158302A1 (en) * 1999-12-09 2003-08-21 Cyric Chaput Mineral-polymer hybrid composition
EP1237585B1 (en) * 1999-12-09 2003-06-18 Biosyntech Canada Inc. Mineral-polymer hybrid composition
US20050042194A1 (en) * 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
WO2002000272A2 (en) * 2000-06-29 2002-01-03 Biosyntech Canada Inc. Composition and method for the repair and regeneration of cartilage and other tissues
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
AU2002221370A1 (en) * 2000-11-15 2002-05-27 Bio Syntech Canada Inc Method for restoring a damaged or degenerated intervertebral disc
ATE306951T1 (de) 2000-11-29 2005-11-15 Allergan Inc Verhinderung von transplantatabstossung im auge
JP2005519873A (ja) * 2001-11-14 2005-07-07 アルザ・コーポレーション カテーテル注入可能なデポー組成物およびそれらの使用
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
IL166418A0 (en) * 2002-07-31 2006-01-15 Alza Corp Injectable depot compositions and uses thereof
EP2030611A1 (en) 2002-07-31 2009-03-04 Alza Corporation Injectable multimodal polymer depot compositions and uses thereof
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
MXPA05010604A (es) * 2003-03-31 2005-11-23 Alza Corp Sistema de administracion osmotica y metodo para disminuir los tiempos de arranque para sistemas de administracion osmotica.
CA2520610A1 (en) * 2003-03-31 2004-10-21 Alza Corporation Osmotic pump with means for dissipating internal pressure
JP2006522133A (ja) * 2003-03-31 2006-09-28 アルザ・コーポレーション 非水性単一相の媒体、及び、そのような媒体を利用するフォーミュレーション
CN1822816A (zh) * 2003-05-30 2006-08-23 阿尔萨公司 可植入的弹性体储库组合物、其用途以及制备方法
US20070184084A1 (en) * 2003-05-30 2007-08-09 Guohua Chen Implantable elastomeric caprolactone depot compositions and uses thereof
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
WO2005107708A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
EP1781264B1 (en) 2004-08-04 2013-07-24 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
EP3173072A1 (en) * 2004-10-01 2017-05-31 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
AR052155A1 (es) * 2004-12-14 2007-03-07 Novartis Ag Compuestos organicos
JP2008524235A (ja) * 2004-12-15 2008-07-10 キューエルティー ユーエスエー，インコーポレイテッド． オクトレオチド化合物の徐放性送達処方物
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006123360A2 (en) * 2005-03-01 2006-11-23 Sun Pharmaceutical Industries Limited Microspheres containing octreotide acetate
AU2006268088B2 (en) * 2005-07-12 2011-05-12 Renovo Ltd Pharmaceutical compositions comprising a TGF-beta superfamily member
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP1948810A4 (en) * 2005-11-04 2010-06-30 Biosyntech Canada Inc COMPOSITION AND METHOD USING CHITOSAN FOR THE EFFICIENT ADMINISTRATION OF NUCLEIC ACIDS TO CELLS
CN101869514B (zh) * 2005-11-16 2012-08-08 学校法人东海大学 用于治疗冠状动脉狭窄的支架
AU2006328950B2 (en) * 2005-12-22 2010-07-29 Novartis Ag Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers
US8236904B2 (en) 2005-12-28 2012-08-07 Ethicon, Inc. Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates
US20070149640A1 (en) * 2005-12-28 2007-06-28 Sasa Andjelic Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
DK2020990T3 (da) 2006-05-30 2010-12-13 Intarcia Therapeutics Inc Strømningsmodulator med en indre kanal til et todelt osmotisk fremføringssystem
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
CA2686137C (en) 2007-05-18 2021-01-12 Durect Corporation Improved depot formulations
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
WO2008149364A2 (en) * 2007-06-07 2008-12-11 Sarah Brenner Methods for diagnosing hypersensitivity reactions
US7923021B2 (en) * 2007-07-24 2011-04-12 University Of Memphis Research Foundation Local delivery method and composition
RU2343908C1 (ru) * 2007-09-05 2009-01-20 Руслан Дмитриевич Илюк Средство для профилактики и лечения алкоголизма и способ его применения
US8470360B2 (en) * 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
CA2705520C (en) * 2007-11-13 2016-06-28 Surmodics Pharmaceuticals, Inc. Viscous terpolymers as drug delivery platform
EP2222281B1 (en) 2007-12-20 2018-12-05 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
AU2013201877B2 (en) * 2008-01-30 2015-01-29 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
PT2247282E (pt) * 2008-01-30 2014-11-11 Novartis Ag Formulação de libertação controlada compreendendo octreotido e três polímeros lineares de polilactido-coglicolido
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US7993666B2 (en) * 2008-04-18 2011-08-09 Warsaw Orthopedic, Inc. Methods and compositions for treating pain comprising a statin
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US8956641B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US20090263456A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods and Compositions for Reducing Preventing and Treating Adhesives
US9072727B2 (en) * 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
US8846770B2 (en) * 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
SMT202000405T1 (it) * 2008-09-04 2020-09-10 Amylin Pharmaceuticals Llc Formulazioni a rilascio prolungato usando veicolanti non acquosi
US9623222B2 (en) * 2008-10-30 2017-04-18 Warsaw Orthopedic, Inc. Drug depot with anchor
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US8951546B2 (en) 2008-12-23 2015-02-10 Surmodics Pharmaceuticals, Inc. Flexible implantable composites and implants comprising same
US9415197B2 (en) 2008-12-23 2016-08-16 Surmodics, Inc. Implantable suction cup composites and implants comprising same
US20100158978A1 (en) * 2008-12-23 2010-06-24 Peter Markland Bioactive spray coating compositions and methods of making and uses thereof
US20100168807A1 (en) * 2008-12-23 2010-07-01 Burton Kevin W Bioactive terpolymer compositions and methods of making and using same
US8974808B2 (en) * 2008-12-23 2015-03-10 Surmodics, Inc. Elastic implantable composites and implants comprising same
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
WO2011031996A2 (en) 2009-09-10 2011-03-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Engineered microparticles for macromolecule delivery
WO2011037623A1 (en) 2009-09-28 2011-03-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20110097380A1 (en) * 2009-10-28 2011-04-28 Warsaw Orthopedic, Inc. Clonidine formulations having antimicrobial properties
DK2498783T3 (en) 2009-11-09 2018-12-10 Allergan Inc COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH
US9993441B2 (en) 2009-12-30 2018-06-12 Surmodics, Inc. Controlled release matrix barrier structure for subcutaneous medical devices
ES2561083T3 (es) 2010-01-22 2016-02-24 Allergan, Inc. Implantes intracamerales de agentes terapéuticos de liberación sostenida
WO2011133370A1 (en) * 2010-04-23 2011-10-27 Medtronic, Inc. Shelf stable pharmaceutical depot
GB2513267B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
WO2012030821A1 (en) * 2010-08-30 2012-03-08 Surmodics Pharmaceuticals, Inc. Terpolymer blends and their use as pressure-sensitive adhesives
WO2012034079A2 (en) * 2010-09-09 2012-03-15 Micell Technologies, Inc. Macrolide dosage forms
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9597412B2 (en) 2011-03-16 2017-03-21 University Of Delaware Injectable delivery system for heparan-binding growth factors
US9005634B2 (en) 2011-04-13 2015-04-14 Medtronic, Inc. Shelf stable pharmaceutical depot
ES2607497T3 (es) * 2011-04-25 2017-03-31 Shandong Luye Pharmaceutical Co., Ltd. Composición de risperidona de microesferas de liberación controlada
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US8969337B2 (en) 2011-12-15 2015-03-03 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
US9642697B2 (en) 2012-04-24 2017-05-09 Snu R&Db Foundation Breast prosthesis allowing controlled release of drug and production method for same
US8822423B2 (en) * 2012-05-17 2014-09-02 Janssen Biotech, Inc. Affinity peptides toward infliximab
KR20200065106A (ko) 2012-09-27 2020-06-08 알레간 인코포레이티드 단백질의 지속된 방출을 위한 생물분해성 약물 전달 시스템
RU2641021C2 (ru) 2013-02-15 2018-01-17 Аллерган, Инк. Имплантат для пролонгированной доставки лекарственного средства
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
BR112015022023B1 (pt) 2013-03-11 2022-12-06 Durect Corporation Composição de liberação controlada injetável compreendendo transportador líquido de alta viscosidade
EP3351239B1 (en) 2013-10-31 2020-04-01 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
CN105764491A (zh) 2013-12-09 2016-07-13 度瑞公司 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016071767A1 (en) 2014-11-07 2016-05-12 Indivior Uk Limited Buprenorphine dosing regimens
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
WO2017015675A1 (en) 2015-07-23 2017-01-26 Envisia Therapeutics, Inc. Glaucoma treatment via intracameral ocular implants
CA3024479A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
BR112018077259A2 (pt) 2016-06-30 2019-06-18 Durect Corporation formulações depot
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
AU2018285975B2 (en) 2017-06-13 2023-11-16 The University Of British Columbia Polymeric paste compositions for drug delivery
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
US11191802B2 (en) 2018-04-06 2021-12-07 AMMA Therapeutics, Inc. Composition for controlled release of therapeutic agents
CN109898236B (zh) * 2019-03-15 2021-12-14 深圳市光远生物材料有限责任公司 一种载药纳米纤维膜及其制备方法和应用
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
EP4277702A1 (en) 2021-01-12 2023-11-22 Durect Corporation Sustained release drug delivery systems and related methods
US20240285769A1 (en) * 2021-06-30 2024-08-29 The University Of North Carolina At Chapel Hill Injectable, biodegradable and removable polymer based drug suspension for ultra-long-acting drug delivery

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797492A (en) * 1972-12-27 1974-03-19 Alza Corp Device for dispensing product with directional guidance member
US3887790A (en) * 1974-10-07 1975-06-03 Vernon H Ferguson Wrap-around electric resistance heater
US3987790A (en) 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS5933320B2 (ja) * 1981-04-03 1984-08-15 株式会社東芝 光学的情報記録媒体
US4443340A (en) * 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
US4985404A (en) * 1984-10-04 1991-01-15 Monsanto Company Prolonged release of biologically active polypeptides
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5085866A (en) * 1988-12-02 1992-02-04 Southern Research Institute Method of producing zero-order controlled-released devices
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5620700A (en) * 1990-10-30 1997-04-15 Alza Corporation Injectable drug delivery system and method
GB9027422D0 (en) * 1990-12-18 1991-02-06 Scras Osmotically driven infusion device
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5288214A (en) * 1991-09-30 1994-02-22 Toshio Fukuda Micropump
WO1993012160A1 (fr) * 1991-12-19 1993-06-24 Mitsui Toatsu Chemicals, Inc. Acide polyhydroxy carboxylique et son procede de production
US5308348A (en) * 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5209746A (en) * 1992-02-18 1993-05-11 Alza Corporation Osmotically driven delivery devices with pulsatile effect
US5456679A (en) * 1992-02-18 1995-10-10 Alza Corporation Delivery devices with pulsatile effect
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
EP1013270A3 (en) * 1992-12-02 2001-03-28 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
US5468253A (en) * 1993-01-21 1995-11-21 Ethicon, Inc. Elastomeric medical device
EP2275089A1 (en) 1993-11-19 2011-01-19 Alkermes Controlled Therapeutics, Inc. Preparation of biodegradable microparticles containing a biologically active agent
US5556905A (en) * 1994-03-30 1996-09-17 Reilly Industries, Inc. Physically-modified degradable thermoplastic compositions
CA2187353C (en) * 1994-04-08 2007-05-22 Gerald L. Yewey Liquid delivery compositions
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
UA10911C2 (uk) * 1994-08-10 1996-12-25 Мале Впроваджувальне Підприємство "Іhтерфалл" Біосумісhий гідрогель
US6113624A (en) * 1995-10-02 2000-09-05 Ethicon, Inc. Absorbable elastomeric polymer
US5639851A (en) * 1995-10-02 1997-06-17 Ethicon, Inc. High strength, melt processable, lactide-rich, poly(lactide-CO-P-dioxanone) copolymers
US6130200A (en) * 1996-12-20 2000-10-10 Alza Corporation Gel composition and methods
US6193991B1 (en) * 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
HUP0201626A3 (en) * 1999-06-04 2004-05-28 Alza Corp Mountain View Implantable gel compositions and method of manufacture
NZ523385A (en) * 2000-06-28 2005-09-30 Atul J Biodegradable vehicles and BAS-loaded delivery systems for use as biodegradable fillers and/or spacers, e.g. artificial skin
AU2002226000A1 (en) * 2000-11-13 2002-05-21 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
WO2002058670A1 (en) 2001-01-25 2002-08-01 Euroceltique S.A. Local anesthetic, and method of use
CA2439120C (en) 2001-02-23 2011-07-05 Genentech, Inc. Erodible polymers for injection
CA2466632C (en) 2001-11-14 2014-02-11 Alza Corporation Injectable depot compositions and uses thereof
JP2005519873A (ja) * 2001-11-14 2005-07-07 アルザ・コーポレーション カテーテル注入可能なデポー組成物およびそれらの使用
WO2003041685A1 (en) * 2001-11-14 2003-05-22 Alza Corporation Injectable depot composition
TWI353854B (en) * 2002-06-25 2011-12-11 Alza Corp Short duration depot formulations
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
EP2030611A1 (en) 2002-07-31 2009-03-04 Alza Corporation Injectable multimodal polymer depot compositions and uses thereof
IL166418A0 (en) * 2002-07-31 2006-01-15 Alza Corp Injectable depot compositions and uses thereof
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105031607A (zh) * 2008-12-15 2015-11-11 诺华股份有限公司 有恒定高暴露水平的奥曲肽贮库制剂
CN105233251A (zh) * 2008-12-15 2016-01-13 诺华股份有限公司 有恒定高暴露水平的奥曲肽贮库制剂
CN102133180A (zh) * 2011-03-18 2011-07-27 黄芳 一种甾体5α-还原酶抑制剂长效注射制剂及其制备方法
CN105358129A (zh) * 2013-03-15 2016-02-24 赫伦治疗有限公司 聚原酸酯和质子惰性溶剂的组合物
CN105848628A (zh) * 2013-12-31 2016-08-10 Pb&B公司 用于身体重构和身体成形的受控释放脂肪酸组合物
CN105848628B (zh) * 2013-12-31 2020-09-18 Pb&B公司 用于身体重构和身体成形的受控释放脂肪酸组合物
CN111548482A (zh) * 2020-04-02 2020-08-18 复旦大学 一氧化氮供体修饰的共聚物、包含其的缓释制剂及其制备方法与应用
CN111548482B (zh) * 2020-04-02 2022-09-13 复旦大学 一氧化氮供体修饰的共聚物、包含其的缓释制剂及其制备方法与应用
CN116270491A (zh) * 2023-03-30 2023-06-23 北京博恩特药业有限公司 一种醋酸亮丙瑞林缓释微球及其制备方法

Also Published As

Publication number Publication date
MA27523A1 (fr) 2005-09-01
EP1581181A2 (en) 2005-10-05
WO2004043432A3 (en) 2004-07-08
MXPA05004927A (es) 2005-09-08
ZA200504529B (en) 2006-08-30
BR0315304A (pt) 2005-08-16
PE20040675A1 (es) 2004-09-25
MY140155A (en) 2009-11-30
NO20052635D0 (no) 2005-06-01
ECSP056249A (es) 2006-10-17
US20040151753A1 (en) 2004-08-05
CA2504608A1 (en) 2004-05-27
JP2006508127A (ja) 2006-03-09
UY28067A1 (es) 2003-12-31
ECSP055838A (es) 2005-09-20
EP1581181B1 (en) 2008-12-24
AU2003295409A1 (en) 2004-06-03
NO20052635L (no) 2005-07-20
AR041913A1 (es) 2005-06-01
NZ539810A (en) 2008-03-28
CL2003002277A1 (es) 2005-05-06
TW200503774A (en) 2005-02-01
ATE418323T1 (de) 2009-01-15
WO2004043432A2 (en) 2004-05-27
RU2005117164A (ru) 2006-01-20
PL377333A1 (pl) 2006-01-23
RU2355385C2 (ru) 2009-05-20
DE60325511D1 (de) 2009-02-05
US7368126B2 (en) 2008-05-06
AU2003295409B2 (en) 2010-02-11
HK1085387A1 (en) 2006-08-25
KR20050088288A (ko) 2005-09-05
CA2504608C (en) 2013-01-08

Similar Documents

Publication Publication Date Title
CN1713890A (zh) 控释储库制剂
US11179326B2 (en) Short duration depot formulations
CN1146402C (zh) 凝胶组合物及方法
CN1822816A (zh) 可植入的弹性体储库组合物、其用途以及制备方法
JP5170935B2 (ja) 注入可能なデポー組成物
US8501215B2 (en) Injectable multimodal polymer depot compositions and uses thereof
US8252303B2 (en) Injectable depot compositions and uses thereof
CA2466632C (en) Injectable depot compositions and uses thereof
JP2007511524A (ja) 薬品送達ビヒクル中の賦形剤
JP2007511516A (ja) 薬品送達ビヒクル中の賦形剤
US20070184084A1 (en) Implantable elastomeric caprolactone depot compositions and uses thereof
CN1671357A (zh) 短暂贮存制剂
CN1886153A (zh) 药物递送媒介物中的赋形剂
HK1086190A (en) Injectable depot compositions and uses thereof
HK1023950B (en) Gel composition and methods

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication